View

The Study

Early Ezetimibe Initiation After Myocardial Infarction Protects Against Later Cardiovascular Outcomes in the SWEDEHEART Registry.

In simple terms

This study looked at medical records of thousands of people who had heart attacks and checked when they started taking ezetimibe. It found that people who started the drug sooner were less likely to have another heart problem, but we can't be sure the drug caused the difference because other factors might explain it.

59%

Analysis score

59/ 72

Maximum 72 for a cohort study.

Where the score came from

Reporting0
Methodology56
Publication100
Statistical77
Study type (basis of the score)
Cohort Study
Level 2b - Individual cohort study
What’s the bottom line?

After a heart attack, people usually take strong cholesterol pills called statins. Adding another pill called ezetimibe soon after helps lower bad cholesterol even more and protects the heart.

Where does this study sit?

Reviews of RCTs (Meta-analyses)

Max 100

Randomized Trials

Max 90

Reviews of Cohort Studies

Max 85

Cohort Studies

Max 72

Reviews of Case-Control Studies

Max 63

Case-Control Studies

Max 58

Cross-Sectional & Case Series

Max 50

Expert Opinion

Max 5
StrongerWeaker
Cohort Studies
Level 2b
59

59 / 100

Quality score

Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.

Cannot establish causation

Save studies & get personalized insights

Create a free account to save this study, track new evidence as it comes in, and get breakdowns of studies in the topics you care about.

Key takeaways

Summary

Based on the study abstract and findings.

  1. 1Starting ezetimibe early cuts the risk of another heart problem nearly in half compared to not using it, which is a big deal for recovery and long-term heart health.
  2. 2Out of 35,826 people: 17% started ezetimibe early (within 12 weeks), 18% later, and 65% never.
  3. 3After one year, 1.8 out of 100 early users had heart problems, vs 2.6 in late users and 4 in those who didn’t use it.

Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data

Publication

Journal

Journal of the American College of Cardiology

Year

2025

Authors

M. Leosdottir, J. Schubert, J. Brandts, S. Gustafsson, T. Cars, Johan Sundström, T. Jernberg, Kausik K. Ray, Emil Hagström

Open Access
31 citations
Analysis v5

Related Content

Claims (6)

Assertion

Ezetimibe helps lower bad cholesterol by stopping your gut from absorbing it, and even though it works well and doesn't cost much, doctors don't use it as much as they could.

Mechanistic
Read analysis
Assertion

If someone has a heart attack and hasn’t taken cholesterol drugs before, waiting more than 12 weeks to start a drug called ezetimibe might increase their risk of future heart problems — though the data isn’t strong enough to be sure.

Correlational
Read analysis
Assertion

If someone has a heart attack and starts taking a cholesterol drug called ezetimibe within 3 months, they’re less likely to have another heart problem in the next 3 years compared to those who wait longer or never start it.

Correlational
Read analysis
Assertion

If you've had a heart attack, starting a cholesterol drug called ezetimibe within 3 months might lower your chance of dying from heart problems over the next 3 years, compared to waiting or not taking it at all.

Correlational
Read analysis
Assertion

Out of nearly 36,000 people hospitalized for heart attacks, most didn't get a cholesterol drug called ezetimibe—even though almost all were already on strong statins. Only about 1 in 6 got it early, and a similar number got it later.

Descriptive
Read analysis
Assertion

People who had a heart attack and started taking a cholesterol drug called ezetimibe early had fewer heart problems over the next year compared to those who started later or didn’t take it at all.

Quantitative
Read analysis
Fit Body Science verdict — we translate health studies into clear verdicts backed by peer-reviewed research.

Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.